HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious therapeutics for the treatment of human diseases while aiming to bring long lasting value to our shareholders. We are now developing new generation of novel drugs for unmet medical needs.
The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers. HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA). ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.
In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL002 (nanoparticle technology) and HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers. HuL002 was in-licensed from Shimadzu Corporation, a long-history renowned Japanese company specialized in clinical diagnosis and medical instruments. HuL003 is a ENO1-based ADC for oncology application.